CompanyCADLNasdaqNeedham, MA

Candel Therapeutics, Inc.

Candel develops off-the-shelf multimodal immunotherapies using genetically modified adenovirus and herpes simplex virus constructs.

SEC EDGAR ClinicalTrials.gov candeltx.com

8-KSep 10Latest SEC filing, period to Sep 6

Sep 10Latest story

September 2026

Candel Therapeutics adds Martine Zimmermann to board ahead of planned BLA filing

Sep 10Partnershipaglatimagene besadenovec Candel Therapeutics, Inc.

August 2026

Candel targets Q4 2026 BLA for prostate cancer therapy, opens NSCLC phase 3 trial

Aug 13Quarterly updateCandel Therapeutics, Inc.